Abstract:Against a background of longstanding concerns that antidepressants may trigger suicidality, the Food and Drug Administration (FDA) in 2004 convened two committees to review the issues. Prior to the second meeting Pfizer posted an extensive ad hominem attack on me on FDA's website. There was no opportunity to post a response. This article covers the points made in response and sheds some light on pharmaceutical company handling of debates about adverse events.
Document Type: Research Article
Publication date: September 1, 2005
More about this publication?
- Ethical Human Psychology and Psychiatry seeks to raise the level of scientific knowledge and ethical discourse, while empowering professionals who are devoted to principled human sciences and services unsullied by professional and economic interests.
- Information for Authors
- Membership Information
- Information for Advertisers
- Free Sample Issue
- Subscribe to this Journal
- Ingenta Connect is not responsible for the content or availability of external websites